During the past decade, University Cancer Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 9 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Cancer Institute" #1 sponsor was "Celgene" with 7 trials, followed by "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "American Regent, Inc." with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Cephalon" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Cancer Institute" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator and "The Lymphoma Academic Research Organisation" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "University Cancer Institute" are "Multiple Myeloma" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Breast Cancer" (1 trials), "Cancer and Chemotherapy Related Anemia" (1 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "University Cancer Institute" in a lesser frequency.

Most popular intervention types in "University Cancer Institute" are "Drug" (14 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Avelumab" (2 trials), "Dexamethasone" (2 trials), "Gemcitabine" (2 trials) and "Pomalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "University Cancer Institute" are 16 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University Cancer Institute". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in University Cancer Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University Cancer Institute, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".